British pharmaceutical company Mylan said Monday it is introducing Paliperidone, a generic version of Janssen's Invega, in extended-release tablets in 1.5 mg, 3 mg, 6 mg and 9 mg dosages in the United States.
Paliperidone is used to treat schizophrenia and schizoaffective disorder in adults and adolescents. It is used in conjunction with monotherapy and as an adjunct to mood stabilizers or antidepressants in adults.
Final approval for the drug was granted to Mylan by the U.S. Food and Drug Administration (FDA) for its abbreviated new drug application.
"We offer a growing portfolio of around 1,400 generic pharmaceuticals and several brand medications," a release from Myland said. "In addition, we offer a wide range of antiretroviral therapies, upon which nearly 50 percent of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in about 145 countries and territories."
More information can be found online at www.mylan.com.
Mylan introduces generic Paliperidone in U.S.